<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>doomandgloom's Comments</title>
    <description>doomandgloom's Comments RSS Syndication from SeekingAlpha.com</description>
    <link>http://seekingalpha.com/user/1034480/comments</link>
    <item>
      <title>Biodel (BIOD) &#8211; Shine or Die</title>
      <link>http://seekingalpha.com/instablog/686356-michael-bryant/127010-biodel-biod-shine-or-die?source=feed#comment-1940159</link>
      <guid isPermaLink="false">1940159</guid>
      <content>
        <![CDATA[really big]]>
      </content>
      <pubDate>Wed, 28 Sep 2011 17:41:33 -0400</pubDate>
      <description>
        <![CDATA[really big]]>
      </description>
    </item>
    <item>
      <title>Biodel: Upside from Potential Linjeta Approval</title>
      <link>http://seekingalpha.com/article/227766/comments?source=feed#comment-1938109</link>
      <guid isPermaLink="false">1938109</guid>
      <content>
        <![CDATA[i have read and was made really interested in this company's product potential through the articles in seeking alpha. i have heavily invested in biodel and heavily lost with every dip, since the CRL and then recently culminating in today's massacre, all in all I lost nearly 70K on this stock. I just can't believe  that indian data fiasco and how I went against common sense and still invested in that stock and doubled down after the CRL because I thought the theory was really good and the molecule must be good too and the upside potential championed by writers of this publication fooled even the physician in me.  Now what? is this really a good theory and just a very bad decision making by administration, such as who would test a product in a country as underdeveloped as India without making precautions for heat and transport and bureaucracy and corruption and a juvenile health care system. And the decision to abandon the Linjeta phase 3 repeats in favor of new molecules. Any thoughts folks other than that I wish I never read those misleading articles by Koscia and others in seeking alpha footnoted by being confidently long on BIOD!! were they? really?]]>
      </content>
      <pubDate>Tue, 27 Sep 2011 23:15:50 -0400</pubDate>
      <description>
        <![CDATA[i have read and was made really interested in this company's product potential through the articles in seeking alpha. i have heavily invested in biodel and heavily lost with every dip, since the CRL and then recently culminating in today's massacre, all in all I lost nearly 70K on this stock. I just can't believe  that indian data fiasco and how I went against common sense and still invested in that stock and doubled down after the CRL because I thought the theory was really good and the molecule must be good too and the upside potential championed by writers of this publication fooled even the physician in me.  Now what? is this really a good theory and just a very bad decision making by administration, such as who would test a product in a country as underdeveloped as India without making precautions for heat and transport and bureaucracy and corruption and a juvenile health care system. And the decision to abandon the Linjeta phase 3 repeats in favor of new molecules. Any thoughts folks other than that I wish I never read those misleading articles by Koscia and others in seeking alpha footnoted by being confidently long on BIOD!! were they? really?]]>
      </description>
    </item>
  </channel>
</rss>
